AOXG   $0.001  0.0 Market Open

Aoxing Pharmaceutical Co Inc
Last Events:

2023-03-30 Trend pattern changed from сужающийся канал to Not found.

2023-03-30 Signal in Stochastic changed from bearish recovery to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: signal line crossed the middle level.

2023-03-30 Signal in MACD changed from bearish recovery to bullish reversal. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-03-30 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-03-30 Signal in EMA100 changed from bearish reversal to n/a.

2023-03-30 Signal in EMA20 changed from bearish reversal to n/a. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-03-30 Trend changed from turning down to flat and down.

2023-03-29 Trend pattern changed from Not found to сужающийся канал.


Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell -
rsi ActivelyBuy - -
macd - - -
stoch - - -
ma20 ActivelyBuy - -
ma50 - - -
ma100 Sell Sell -
Candlestick PatternAug. 20, 2021 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US03740A1060
Website https://axzyen.icm.cn
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.